Medical Device Accelerator
The deadline to apply for the 2018 Medical Device Accelerator has passed. Applicants can expect to hear from our team about the status of their submission by early October. Check soon for information about this year's winners.
- Neuro devices: monitoring and therapeutics
- Delivery platforms: drug and gene therapy
- Connected health: sensors, AI/ML, devices, and systems
The Medical Device Accelerator, sponsored by the Perelman School of Medicine and Penn Medicine Center for Health Care Innovation, in partnership with the Penn Center for Innovation and Penn Health-Tech, empowers entrepreneurs, clinicians, and researchers at Penn Medicine to create and commercialize innovative medical devices to address unmet clinical needs, improve patient outcomes and reduce the cost of care. The program supports faculty and staff in transforming their "paper napkin drawing" to a final product ready for clinical use. We also partner with business accelerators such as DevelUPmed to help participants make the transition from device to company after the program concludes.
Teams selected to participate receive:
How it works
IP and licensing compensation
Individuals participating in the Medical Device Accelerator are subject to the Patent and Tangible Research Property Policies and Procedures of the University of Pennsylvania.
Dan Holena, MD: Patients with enterocutaneous fistula (ECF) may not be operative candidates for months or years and suffer from debilitating medical complications requiring lengthy inpatient stays. Intravenous nutrition alone costs $90K-$120K annually and is not nutritionally sufficient. Creating a device to collect proximal gastrointestinal secretions and ingested food and refeed materials distally will allow patients to eat normally and remain in a non-hospital setting.
2017 investigational projects
New this year! Investigational projects will receive low-touch support to reach milestones and then be considered for advancement to an active project.
Michael Milone, MD, PhD and Saba Ghassemi, PhD: A viable strategy for blood cancer is immunotherapy involving adoptive cellular transfer (ACT) including CAR-T therapies. Magnetic beads with stimulatory antibodies that activate and drive T cell proliferation ex vivo represent the primary platform used for ACT manufacturing today. Although bead-based ACT manufacturing has been successfully scaled into cGMP processes, the effectiveness of this platform for manufacturing in patients with leukemia, where leukemic cell frequencies vastly exceed T cell frequencies, is significantly reduced. Michael Milone, MD, PhD and Saba Ghassemi, PhD are working to develop a new cell therapy manufacturing device for T cell isolation, activation and transduction that is automated, regulated and fully enclosed in order to reduce labor and manufacturing cost. The device they’ve designed has the ability to select T cells from leukemia-rich blood samples and activate cells in a single step for both ex vivo propagation and genetic engineering.
Ari Brooks, MD; Rahul Mangharam, PhD; Han Jun Kim; Richard Sensenig; and Ezra Brooks: Measuring urine output data serves as a reliable, inexpensive and effective way to measure patient well-being. Urine output is an indicator of acute kidney injury, which occurs in 30% of ICU patients. Current urimeters are read visually and emptied manually every hour, with care team members recording data on paper. Ari Brooks, MD; Rahul Mangharam, PhD; Han Jun Kim; Richard Sensenig; and Ezra Brooks have designed a digital urimeter based on electrical continuity that calculates the total volume in the urimeter container, provides a real-time display and integrates data directly into the patient EMR.
Perry Dubin, MD, MPH: Ventilator-associated pneumonia (VAP) is a hospital-acquired infection that affects 15-20% of the 3 million ventilated patients in the United States annually. VAP is associated with mortality of 30% and significant morbidity - including extended Medical Intensive Care Unit (MICU) and hospital stays. However, clinical studies on patient recumbency have shown that recumbency at 30-45% is associated with significant reduction in VAP. To tackle this issue, Perry Dubin, MD, MPH created Angulus. Angulus is a small 1”x2” biosensor that affixes via silicone adhesive directly to the chest of a patient. It contains a disposable inclinometer that digitally measures patient recumbency and has the ability to wirelessly transmit information to electronic health records and display data on vital sign and telemetry monitors.
James Carey, MD, MPH: Nationally, knee arthroscopy procedures are performed more than 500,000 times per year. Metallic biters are the tools currently utilized to perform the procedure. However, metallic biters are metallic and rigid, which minimizes access to the meniscus and maximizes the risk of damage to the articular cartilage. James Carey, MD, MPH is working to create a flexible meniscal biter to permit more comprehensive and safer treatment of the meniscus during knee arthroscopy procedures.
Jake Brenner, MD, PhD; Marek Swoboda, PhD; and Perry Dubin, MD, MPH: Chronic obstructive pulmonary disease (COPD), popularly called emphysema, causes 15 million Americans to suffer years of intolerable shortness of breath (SOB). In these patients, prior smoking changes the lung structure so that they cannot breathe when engaged in activity. Jake Brenner, MD, PhD; Marek Swoboda, PhD; and Perry Dubin, MD, MPH are working to create a wearable mechanical breathing assist device (AIR-AD) to help the 2 million Americans who suffer from severe COPD. AIR-AD is a respiratory assist device that fits like a shell over the anterior chest and abdomen and offloads the work of breathing (WOB). With each breath in, AIR-AD generates a vacuum that helps lift the chest and abdomen, drawing air in. With each breath out, AIR-AD increases pressure over the chest and helps the patient breathe out faster. By assisting with WOB, AIR-AD helps reduce the feeling of SOB, enabling patients to once again engage in life.